Beigene, LTD 8-K filings

BeiGene has filed its 2024 interim report with the Shanghai Stock Exchange, providing a breakdown of research and development expenses under both PRC and U.S. GAAP.

BeiGene reports a 56% increase in total revenue to $929 million and achieves non-GAAP operating income in the second quarter of 2024, driven by strong sales of BRUKINSA.

BeiGene has announced the appointment of Aaron Rosenberg as its new Chief Financial Officer, succeeding Julia Wang, who is departing to pursue other opportunities.

BeiGene, Ltd. shareholders approved amendments to the 2016 Share Option and Incentive Plan and the 2018 Employee Share Purchase Plan, along with other key resolutions, at their annual general meeting on June 5, 2024.

BeiGene's first quarter 2024 results show significant revenue growth, particularly from BRUKINSA sales, and progress towards sustainable profitability.

BeiGene has filed its 2023 Annual Report with the Shanghai Stock Exchange, providing additional financial information prepared under PRC GAAP, and highlighting key differences from U.S. GAAP.

The European Commission has approved BeiGene's tislelizumab for the treatment of non-small cell lung cancer across three indications, including firstand second-line use.

BeiGene has appointed Titus Ball as its new principal accounting officer, effective March 19, 2024, and amended its Independent Director Compensation Policy, increasing cash retainers for the Nominating and Corporate Governance Committee.

The FDA has approved BeiGene's TEVIMBRA as a monotherapy for adult patients with advanced esophageal squamous cell carcinoma after prior chemotherapy.

BeiGene has initiated patent infringement lawsuits against Sandoz and MSN in response to their Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of BRUKINSA.

BeiGene announced record total revenues of $2.5 billion for full-year 2023, a 74% increase year-over-year, driven by strong sales of its hematology drug BRUKINSA.

BeiGene has appointed Olivier Brandicourt to its Board of Directors, filling the vacancy left by Thomas Malley's resignation.